3SBio Inc. (HKG:1530)
Hong Kong · Delayed Price · Currency is HKD 16.06
-0.06 (-0.37%)
Sep 1, 2026, 4:08 PM HKT
3SBio Revenue
3SBio had revenue of 4.53B CNY in the half year ending June 30, 2026, with 3.11% growth. This brings the company's revenue in the last twelve months to 17.87B, up 96.89% year-over-year. In the year 2025, 3SBio had annual revenue of 17.70B with 94.29% growth.
Revenue (ttm)
17.87B CNY
Revenue Growth
+96.89%
P/S Ratio
1.94
Revenue / Employee
2.94M CNY
Employees
6,068
Market Cap
40.02B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 17.70B | 8.59B | 94.29% |
| Dec 31, 2024 | 9.11B | 1.29B | 16.53% |
| Dec 31, 2023 | 7.82B | 950.20M | 13.84% |
| Dec 31, 2022 | 6.87B | 483.73M | 7.58% |
| Dec 31, 2021 | 6.38B | 794.37M | 14.22% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sino Biopharmaceutical | 38.91B |
| RemeGen | 9.24B |
| Shanghai Henlius Biotech | 8.58B |
| Genscript Biotech | 6.63B |
| Akeso | 3.98B |
| Shanghai Junshi Biosciences | 3.49B |
| InnoCare Pharma | 3.21B |
| Biocytogen Pharmaceuticals (Beijing) | 1.96B |
3SBio News
- 12 days ago - 3SBio Earnings release: H1 2026 - Filings
- 5 months ago - 3SBio Earnings release: H2 2025 - Filings
- 5 months ago - 3SBio Annual report: H2 2025 - Filings
- 5 months ago - 3SBio Slides: H2 2025 - Filings
- 1 year ago - Pfizer Signs $6B Deal with 3SBio for China-Based Cancer Drug - TipRanks